Advanced search
Publication Cover
Leukemia & Lymphoma Volume 58, 2017 - Issue 11
Submit an article Journal homepage
669
Views
15
CrossRef citations to date
0
Altmetric
Original Articles: Research

Patterns of treatment and costs associated with transfusion burden in patients with myelodysplastic syndromes

Amy E. DeZernSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA; Correspondence[email protected]
View further author information
,
Gary BinderCelgene Corporation, Summit, NJ, USA; View further author information
,
Syed RizviCelgene Corporation, Summit, NJ, USA; View further author information
,
Frank A. CorvinoGenesis Research, Hoboken, NJ, USAView further author information
,
Steven R. ArikianGenesis Research, Hoboken, NJ, USAView further author information
,
Andy SurinachGenesis Research, Hoboken, NJ, USAView further author information
,
Jianyi LeeGenesis Research, Hoboken, NJ, USAView further author information
&
B. Douglas SmithSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA; View further author information
 show all
Pages 2649-2656 | Received 29 Nov 2016, Accepted 14 Mar 2017, Published online: 09 May 2017

References

  • Fenaux P, Haase D, Sanz GF, et al. Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25:iii57–iii69.
  • Triantafyllidis I, Ciobanu A, Stanca O, et al. Prognostic factors in myelodysplastic syndromes. Mædica (Buchar). 2012;7:295–302.
  • Gupta P, LeRoy SC, Luikart SD, et al. Long-term blood product transfusion support for patients with myelodysplastic syndromes (MDS): cost analysis and complications. Leuk Res. 1999;23:953–959.
  • Kao JM, McMillan A, Greenberg PL. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes. Am J Hematol. 2008;83:765–770.
  • Malcovati L, Della Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. JCO. 2005;23:7594–7603.
  • Jabbour E, Kantarjian HM, Koller CA, et al. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes. Cancer. 2008;112:1089–1095.
  • Jansen AJ, Essink-Bot ML, Beckers EA, et al. Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes. Br J Haematol. 2003;121:270–274.
  • Germing U, Lauseker M, Hildebrandt B, et al. Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study. Leukemia. 2012;26:1286–1292.
  • Falantes JF, Calderón C, Márquez Malaver FJ, et al. Clinical prognostic factors for survival and risk of progression to acute myeloid leukemia in patients with myelodysplastic syndromes with <10% marrow blasts and non-unfavorable cytogenetic categories. Clin Lymphoma Myeloma Leuk. 2013;13:144–152.
  • Harnan S, Ren S, Gomersall T, et al. Association between transfusion status and overall survival in patients with myelodysplastic syndromes: a systematic literature review and meta-analysis. Acta Haematol. 2016;136:23–42.
  • Abel GA, Efficace F, Buckstein RJ, et al. Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS). Haematologica. 2016;101:781–788.
  • Chan LS, Shapiro R, Buckstein R, et al. Initial transfusion intensity predicts survival in myelodysplastic syndrome. Leuk Lymphoma. 2014;55:2296–2300.
  • Pereira A, Nomdedeu M, Aguilar JL, et al. Transfusion intensity, not the cumulative red blood cell transfusion burden, determines the prognosis of patients with myelodysplastic syndrome on chronic transfusion support. Am J Hematol. 2011;86:245–250.
  • Goldberg SL, Chen E, Sasane M, et al. Economic impact on US Medicare of a new diagnosis of myelodysplastic syndromes and the incremental costs associated with blood transfusion need. Transfusion. 2012;52:2131–2138.
  • Frytak JR, Henk HJ, De Castro CM, et al. Estimation of economic costs associated with transfusion dependence in adults with MDS. Curr Med Res Opin. 2009;25:1941–1951.
  • Cogle CR. Incidence and burden of the myelodysplastic syndromes. Curr Hematol Malig Rep. 2015;10:272–281.
  • International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) [Internet]. [cited 1 Mar 2017]. Available from: https://www.cdc.gov/nchs/icd/icd9cm.htm.
  • Della Porta MG, Malcovati L, Strupp C, et al. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica. 2011;96:441–449.
  • Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383.
  • Deyo R. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–619.
  • Zeidan AM, Gore SD, McNally DL, et al. Lenalidomide performance in the real world: patterns of use and effectiveness in a Medicare population with myelodysplastic syndromes. Cancer. 2013;119:3870–3878.
  • Arikian SR, Milentijevic D, Binder G, et al. Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma. Curr Med Res Opin. 2015;31:1105–1115.
  • Platzbecker U, Hofbauer LC, Ehninger G, et al. The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes. Leuk Res. 2012;36:525–536.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.